Biomarkers in Barrett esophagus.

Area of Science:

• Gastroenterology
• Oncology
• Molecular Biology

Background:

• Barrett esophagus is a premalignant condition with a risk of progressing to adenocarcinoma.
• Current risk stratification relies on histological dysplasia, but subsets of patients face higher risks.
• New biomarkers are under investigation to improve cancer risk assessment in Barrett esophagus.

Purpose of the Study:

• To review biological markers for their relevance in Barrett esophagus.
• To assess the potential of biomarkers in identifying high-risk patients.
• To explore the use of biomarkers as surrogate markers for treatment monitoring.

Main Methods:

• Review of existing literature on biological markers associated with cancer development.
• Analysis of factors such as cell proliferation, genetic abnormalities, and protein expression.
• Correlation of biomarkers with cancer development and treatment response in Barrett esophagus.

Main Results:

• Several biomarkers, including cell proliferation markers, cyclooxygenase 2, growth factors, oncogenes, and genetic abnormalities like aneuploidy, are associated with cancer development.
• While prospective studies are lacking for most biomarkers, abnormal ploidy status, P16 and P53 gene abnormalities, and allelic losses are well-documented.
• These markers show potential for both risk stratification and monitoring treatment efficacy.

Conclusions:

• Biological markers hold promise for improving risk stratification in Barrett esophagus.
• Further evaluation and prospective studies are needed to validate these biomarkers.
• Abnormal ploidy, P16/P53 gene abnormalities, and allelic losses are currently the most documented indicators.